Domenica Lorusso, Francesco Raspagliesi, Dominique Ronzulli, Giorgio Valabrega, Nicoletta Colombo, Carmela Pisano, Chiara Cassani, Germana Tognon, Stefano Tamberi, Giorgia Mangili, Serafina Mammoliti, Ugo De Giorgi, Filippo Greco, Anna Maria Mosconi, Enrico Breda, Grazia Artioli, Claudia Andreetta, Claudia Casanova, Rita Ceccherini, Antonio Frassoldati, Vanda Salutari, Serena Giolitto, Giovanni Scambia
PURPOSE: Literature evidence suggests that trabectedin monotherapy is effective in patients with recurrent ovarian cancer (OC) presenting BRCA mutation and/or BRCAness phenotype. METHODS: A prospective, open-label, randomized phase III MITO-23 trial evaluated the activity and safety of trabectedin 1.3 mg/m2 given once every 3 weeks (arm A) in BRCA 1/2 mutation carriers or patients with BRCAness phenotype (ie, patients who responded to ≥two previous platinum-based treatments) with recurrent OC, primary peritoneal carcinoma, or fallopian tube cancer in comparison with physician's choice chemotherapy in the control arm (arm B; pegylated liposomal doxorubicin, topotecan, gemcitabine, once-weekly paclitaxel, or carboplatin)...
February 5, 2024: Journal of Clinical Oncology